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Abstract 
Cortical hyperexcitability and mislocalization of the RNA-binding protein TDP43 are highly-
conserved features in amyotrophic lateral sclerosis (ALS). Nevertheless, the relationship between 
these phenomena remains poorly defined. Here, we show that hyperexcitability recapitulates 
TDP43 pathology by upregulating shortened (s) TDP43 splice isoforms. These truncated isoforms 
accumulate in the cytoplasm, where they form insoluble inclusions that sequester full-length 
TDP43 via preserved N-terminal interactions. Consistent with these findings, sTDP43 
overexpression is toxic to mammalian neurons, suggesting that neurodegeneration results from 
complementary gain- and loss-of-function mechanisms. In humans and mice, sTDP43 transcripts 
are enriched in vulnerable motor neurons, and we observed a striking accumulation of sTDP43 
within neurons and glia of ALS patients. These studies uncover a hitherto unknown role of 
alternative TDP43 isoforms, and indicate that sTDP43 production may be a key contributor to the 
susceptibility of motor neurons in ALS. 
 
Introduction 
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder in which the 
progressive loss of motor neurons results in paralysis and respiratory failure1. There is no disease-
modifying therapy for ALS, and its heterogeneous biochemical, genetic, and clinical features 
complicate the identification of therapeutic targets. However, the cytoplasmic mislocalization and 
accumulation of TDP43 (TAR DNA-binding protein of 43 kD), a nuclear RNA-binding protein 
integrally involved in RNA metabolism, is observed in >90% of individuals with ALS2. Moreover, 
while mutations in the gene encoding TDP43 (TARDBP) only account for 2-5% of ALS cases, 
mutations in several other ALS-associated genes including C9ORF723, ANG4, TBK15, PFN16, 
UBQLN27, VCP8, and hnRNPA2/B19 result in TDP43 pathology. 
TDP43 is an essential protein involved in several RNA processing events, including 
splicing, translation, and degradation. In keeping with these fundamental functions, TDP43 levels 
and localization are tightly regulated and critical for cell health. TDP43 knockout animals exhibit 
neurodegeneration and behavioral deficits10–13, while TDP43 overexpression results in 
neurodegeneration in primary neuron14,15, mouse16,17, rat18,19, Drosophila20,21, zebrafish22,23, and 
primate models24,25. Furthermore, mislocalization of TDP43 to the cytoplasm is sufficient to drive 
cell death14. Taken together, this suggests that even small changes to TDP43 levels and 
localization are highly predictive of neurodegeneration. 
Hyperexcitability, or an increase in neuronal activity, is also a conserved feature in both 
familial and sporadic ALS26. Cortical hyperexcitability precedes symptom onset in some cases26, 
and the degree of motor neuron excitability is a strong predictor of disease progression27,28. Such 
hyperexcitability arises from a loss of cortical inhibition26,29–33 in combination with intrinsic 
differences in channel expression, content, and activity within motor neurons themselves26,28,34,35. 
Emphasizing the contribution of hyperexcitability to disease, riluzole—one of two available 
therapies for ALS—is a sodium channel antagonist that partially rescues hyperexcitability36. 
Animal models of ALS recapitulate key features of hyperexcitability37–39, including an increase in 
motor neuron activity that precedes the onset of motor deficits37,39,40 and reduced activity following 
treatment with riluzole41. Hyperexcitability is also observed in iPSC-based ALS models42,43, 
though other reports suggest that it may be a transient or developmental phenomenon43,44. 
Despite the prevalence of both TDP43 pathology and hyperexcitability in ALS, the 
relationship between these phenomena remains poorly defined. Here, we utilize an iPSC-derived 
neuron (iNeuron) model system to demonstrate that hyperexcitability drives TDP43 pathology 
characteristic of ALS via the upregulation of atypical, shortened TDP43 isoforms. Using multiple 
model systems and human post-mortem material, we show that these unusual isoforms are 
exported from the nucleus, form insoluble cytoplasmic inclusions, are neurotoxic, and are 
enriched in ALS patient tissue, thereby directly implicating alternative TDP43 isoforms in ALS 
pathogenesis. 
 
Results 
TDP43 is regulated by neuronal activity 
To investigate disease mechanisms related to hyperexcitability in human neurons, we 
established an induced pluripotent stem cell (iPSC) derived neuron (iNeuron) model. 
Transcription activator-like endonucleases (TALENs) specific for the CLYBL safe harbor locus 
were used to introduce the transcription factors Neurogenin 1 and 2 (Ngn1-2) under a doxycycline 
(dox)-inducible promoter (Figure 1A). Expression of Ngn1-2 is sufficient to drive the rapid 
differentiation of iPSCs into iNeurons that display immunocytochemical and electrophysiological 
properties of glutamatergic, excitatory forebrain-like neurons45–47 (Figure 1B). Consistent with this, 
within 2 weeks of dox addition iNeurons adopt a neuronal morphology and stain positive for the 
neuronal markers Vglut1 and Tuj1 (Figure 1C). We further validated the maturity of neurons 
differentiated in this manner using an iPSC line that stably expresses the fluorescent calcium 
indicator gCaMP6f in addition to dox-inducible Ngn1-248. Because time-dependent changes in 
gCaMP6f fluorescence correlate with action potentials, we monitored neuronal activity indirectly 
and non-invasively in iNeurons by fluorescence microscopy. Two to three weeks following dox 
addition, iNeurons displayed a low level of spontaneous activity that was significantly increased 
with bath application of the neurotransmitter glutamate or the potassium channel blocker 
tetraethylammonium (TEA; Figure 1D-F). Conversely, activity was inhibited by application of the 
sodium channel blocker tetrodotoxin (TTX). Though glutamate dramatically increased neuronal 
activity, it proved to be toxic even at low doses (data not shown). In comparison, iNeurons treated 
with TEA showed a smaller, sustained increase in activity without significant cell death (Figure 
1G). Thus, TEA was utilized in future studies of activity-dependent TDP43 regulation. 
To explore a potential connection between hyperexcitability and TDP43 pathology, we 
pharmacologically stimulated or blocked activity in iNeuron cultures and then examined changes 
in TDP43 levels via immunocytochemistry (ICC) using an antibody directed against the TDP43 
N-terminus. To quantitatively gauge differences in neuronal TDP43, we utilized MAP2 staining to 
generate cellular regions of interest (ROIs), and measured TDP43 immunoreactivity within 
individual neurons. TEA-treated iNeurons showed a significant increase in TDP43 
immunoreactivity while TTX-treated iNeurons exhibited a reduction, suggesting a bidirectional 
relationship between TDP43 abundance and neuronal activity (Figure 1H, I). An analogous 
relationship was observed in rodent primary mixed cortical neurons treated with glutamate or the 
GABA receptor antagonist bicuculline (Supplemental Figure 1A).  
Unexpectedly, when we repeated these studies using an antibody directed against the 
TDP43 C-terminus, we failed to identify significant activity-dependent changes in protein 
abundance (Figure 1J, K), and also noted prominent differences in subcellular TDP43 distribution 
identified by each antibody (Figure 1H, J). Immunostaining with N-terminal antibodies revealed 
punctate, cytoplasmic TDP43 superimposed upon nuclear TDP43 in both iNeurons (Figure 1H) 
and rodent primary mixed cortical neurons treated with bicuculline (Supplemental Figure 1B). 
However, only nuclear TDP43 was detectable using C-terminal TDP43 antibodies (Figure 1J). A 
survey of commercially available antibodies with known epitopes revealed similar trends in 
localization: antibodies that recognize the TDP43 N-terminus are more likely to display nuclear 
and cytoplasmic staining patterns49–51, while antibodies specific to the C-terminus primarily show 
nuclear TDP4352,53. 
Given the variability in antibody specificity and potential difficulties in reproducing results 
using different antibodies54,55, we validated our findings by fluorescently-labeling native TDP43 in 
iPSCs using CRISPR/Cas9 genome engineering. To minimize off-target effects, we used a dual-
nickase approach56 to fuse the green-fluorescent protein Dendra2 to either the N-terminus (D2-
TDP43) or the C-terminus (TDP43-D2) of endogenous TDP43 in human iPSCs (Figure 2A, 
Supplemental Figure 2). D2-TDP43 and TDP43-D2 iPSCs were differentiated into iNeurons as 
described before (Figure 2B, C), and neuronal activity was pharmacologically stimulated or 
blocked using TEA or TTX, respectively. After 48h, we visualized native Dendra2-labeled TDP43 
by fluorescence microscopy, noting a bidirectional relationship between D2-TDP43 abundance 
and neuronal activity (Figure 2D) that was nearly identical to what we observed using antibodies 
that recognize the TDP43 N-terminus (Figure 1H, I). In comparison, there were no significant 
activity-dependent changes in TDP43-D2 (Figure 2E), consistent with our inability to detect 
changes upon staining with antibodies raised against the TDP43 C-terminus (Figure 1J, K). These 
data provide convincing evidence for TDP43 species harboring the N- but not the C-terminus that 
are regulated by neuronal activity. Additionally, the distinctive TDP43 distribution patterns 
revealed by N- and C-terminal reactive antibodies were reflected by the localization of Dendra2-
tagged native TDP43: D2-TDP43 appeared both cytoplasmic and nuclear (Figure 2B), while the 
distribution of TDP43-D2 was limited to the nucleus (Figure 2C). 
Collectively, these results suggest that neuronal activity elicits an increase in cytoplasmic 
TDP43 that lacks a C-terminus. In contrast to what we observed with N-terminal TDP43, there 
was no reciprocal activity-dependent change in C-terminal TDP43 abundance or localization by 
immunocytochemistry, and we failed to observe any differences in C-terminally labeled TDP43-
D2 upon addition of TEA or TTX, arguing against a cleavage event. Previous studies 
demonstrated that neuronal activity regulates the abundance of similar RNA-binding proteins 
through alternative splicing57,58. We therefore considered the possibility that activity gives rise to 
distinct TDP43 isoforms through alternative splicing.  
 
Hyperexcitability drives TARDBP alternative splicing 
Using available RNA-seq data obtained from human cell lines59, we identified two 
alternatively spliced TARDBP isoforms predicted to encode C-terminally truncated or shortened 
(s) TDP43 isoforms (Figure 3A). Identical sTDP43 splice isoforms (TDP-S6 and TDP-S7) were 
detected in previous studies of TARDBP splicing60,61. Both sTDP43-specific splice donors are 
located within TARDBP exon 6 and differ by only 9 bp; each utilizes an identical splice acceptor 
within the TARDBP 3’ untranslated region (UTR), thereby eliminating the majority of exon 6 
(Figure 3B). We designed primers specific for both sTDP43 splice junctions as well as full-length 
(fl) TDP43 utilizing the canonical termination codon within exon 6, and performed qRT-PCR to 
examine changes in splice isoform abundance in vehicle-, TEA-, or TTX-treated human iNeurons. 
Both sTDP43 isoforms were not only detectable in iNeurons, but also significantly upregulated by 
TEA-treatment and downregulated by TTX (Figure 3C), suggesting that the bidirectional change 
in N-terminal TDP43 observed in TEA- or TTX-treated iNeurons may be due to altered expression 
of sTDP43 transcript isoforms. Transcripts encoding flTDP43 were also upregulated by TEA, but 
not reduced by TTX (Figure 3C). Thus, although all TARDBP transcript variants increase with 
neuronal activity, only sTDP43 isoforms demonstrate a bidirectional response to neuronal activity 
and corresponding changes at the protein level, perhaps due to selective autoregulation or 
nuclear retention of flTDP43-encoding transcripts61–63.  
The two sTDP43 transcripts (sTDP43-1 and -2) encode proteins that differ by only 3 amino 
acids, and both lack residues that correspond to the entirety of the glycine rich domain (residues 
281-414 of flTDP43)64. Usage of the common splice acceptor for sTDP43-1 and -2 located within 
the TARDBP 3’UTR results in the inclusion of a new exon encoding a unique 18-amino acid C-
terminus not found in flTDP43 (Figure 3D). These splicing events and the novel C-terminus are 
highly conserved at both the transcript (Supplemental Table 1) and protein (Supplemental Table 
2) levels in humans, non-human primates, and lesser mammals. Despite this, and the previous 
identification of sTDP43 splice variants in human and murine tissues60,61,64,65, the pathways 
governing their expression remain unknown. Our results demonstrate that these variants are 
dynamically and bidirectionally regulated by neuronal activity, with neuronal hyperactivity resulting 
in a significant upregulation of sTDP43 at the RNA and protein levels. 
 
sTDP43 is cytoplasmically localized due to a putative NES in its C-terminal tail 
To investigate sTDP43 localization, we transfected rodent primary mixed cortical neurons 
with diffusely localized mApple to enable visualization of neuronal cell bodies and processes, as 
well as constructs encoding flTDP43 or sTDP43-1 isoforms fused to an EGFP tag. We then 
imaged cultures by fluorescence microscopy to examine the localization of each isoform. flTDP43 
appeared to be primarily nuclear in distribution, as expected, but sTDP43 demonstrated 
prominent cytoplasmic deposition (Figure 4A). The dramatic difference in sTDP43 localization 
was unanticipated given the presence of an intact nuclear localization signal (NLS) within the 
sTDP43 N-terminus (Figure 3D), and hinted at the presence of a potential nuclear export signal 
(NES) within the novel sTDP43 C-terminus. 
To explore this possibility, we utilized NetNES1.1, an algorithm that employs neural 
networks and hidden Markov models to predict NES-like motifs from protein primary structure66. 
This analysis uncovered a series of amino acids near the sTDP43 C-terminal pole that could 
potentially act as an NES (Figure 4B). We then tested the function of this putative NES through 
three complementary experiments. First, we altered the putative NES within sTDP43 by site-
directed mutagenesis (TSLKV→GGGGG) and expressed this construct (sTDP43(mNES)) in 
rodent primary neurons (Figure 4A). Protein localization was assessed by automated microscopy, 
using scripts that measure fluorescence separately within cytoplasmic and nuclear ROIs, and 
calculate a nuclear-cytoplasmic ratio (NCR) for TDP43 in each transfected neuron14,15. While 
sTDP43 was localized to both the nucleus and cytoplasm, sTDP43(mNES) displayed a primarily 
nuclear distribution, more so even than flTDP43, suggesting that the putative NES is necessary 
for cytoplasmic deposition of sTDP43 (Figure 4C). Second, we fused EGFP to the 18-amino acid 
tail of sTDP43 (EGFP-tail), or a version of the sTDP43 tail harboring a mutated NES (EGFP-
tail(mNES)) (Figure 4D). For comparison, we also expressed Shuttle-RFP, a construct with a 
strong NES and a weak NLS that exhibits a predominant cytoplasmic distribution67. Addition of 
the sTDP43 tail was sufficient to partially exclude EGFP-tail from the nucleus, but this change in 
distribution was eliminated by mutating the residues making up the putative NES in EGFP-
tail(mNES) (Figure 4E). Lastly, we asked whether sTDP43’s cytoplasmic distribution arises from 
the absence of a nuclear retention signal encoded within the canonical TDP43 C-terminus68, or 
the presence of an active NES within the sTDP43 tail. Fusing the sTDP43 tail to flTDP43 markedly 
shifted the distribution of flTDP43 to the cytoplasm (Supplemental Figure 3), suggesting that 
sTDP43 localization is dictated primarily by the C-terminal NES, and not the lack of a nuclear 
retention signal. Together, these data indicate that the novel C-terminus of sTDP43 encodes a 
functional NES that facilitates cytoplasmic accumulation of sTDP43. 
  
sTDP43 overexpression is neurotoxic 
TDP43 mislocalization is a widely observed phenomenon in ALS, and cytoplasmic TDP43 
is a strong predictor of cell death14. Given these data and the largely cytoplasmic localization of 
sTDP43, we surmised that sTDP43 accumulation would be toxic to mammalian neurons. We 
therefore utilized automated microscopy in conjunction with survival analysis to track individual 
neurons prospectively over time and determine their risk of death in an unbiased and high-
throughput manner14,15,59,69,70. Rodent primary mixed cortical neurons were transfected with 
mApple and EGFP-tagged TDP43 isoforms and imaged by fluorescence microscopy at 24h 
intervals for 10d71. Custom scripts were used to automatically generate ROIs corresponding to 
each cell and determine time of death based on rounding of the soma, retraction of neurites, or 
loss of fluorescence (Figure 5A). The time of death for individual neurons was used to calculate 
the risk of death in each population relative to a reference group, in this case neurons expressing 
EGFP71,72. In keeping with the results of previous studies, flTDP43 overexpression resulted in a 
significant increase in the risk of death in comparison to EGFP alone (p<2x10-16). sTDP43-1 
overexpression elicited an analogus increase in the risk of death for transfected neurons (p<2x10-
16), suggesting that sTDP43 and flTDP43 display similar toxicity when overexpressed in neurons 
(Figure 5B). 
  
sTDP43 alters endogenous TDP43 localization 
TDP43 dimerizes via its N-terminus52,73–79, and because sTDP43 is exported from the 
nucleus and contains an intact N-terminus we questioned whether sTDP43 might bind to and 
sequester endogenous flTDP43 within the cytoplasm. To determine if sTDP43 is capable of 
interacting with endogenous flTDP43, we transfected HEK293T cells with HaloTag-labeled 
sTDP43-1 or flTDP43 and isolated the fusion proteins using HaloLink resin (Figure 6A). We 
detected equivalent amounts of endogenous flTDP43 in eluates from sTDP43-HaloTag and 
flTDP43-HaloTag, indicating that sTDP43 effectively binds endogenous flTDP43 (Figure 6B).  
We also examined the interaction between sTDP43 and endogenous TDP43 by ICC. 
HEK293T cells were transfected with EGFP or EGFP-tagged sTDP43, immunostained using a C-
terminal TDP43 antibody that recognizes endogenous TDP43 but not sTDP43, and imaged by 
confocal fluorescence microscopy (Figure 6C). HEK293T cells overexpressing EGFP-tagged 
sTDP43 displayed cytoplasmic inclusions that strongly colocalize with endogenous TDP43. 
Moreover, we observed significant reductions in nuclear endogenous TDP43 in association with 
cytoplasmic TDP43 deposition (Figure 6D, E), suggesting cytoplasmic sequestration of 
endogenous TDP43 by sTDP43. Rodent primary mixed cortical neurons overexpressing sTDP43-
1 displayed a similar depletion of endogenous TDP43 from the nucleus (Figure 6F, G). Thus, 
sTDP43 overexpression results in both cytoplasmic deposition and nuclear clearance of 
endogenous TDP43, recapitulating signature features of ALS pathology and implying that both 
gain- and loss-of-function mechanisms contribute to toxicity. 
In sTDP43-transfected cells, we observed significant variability in the degree of TDP43 
nuclear exclusion and cytoplasmic aggregation, which we suspected was due to differences in 
sTDP43 expression among transfected cells. Because the abundance of a fluorescently-labeled 
protein is directly proportional to the intensity of the fluorescent tag80, we estimated sTDP43 
expression in each cell by measuring single-cell EGFP intensity, and separated cells into 5 bins 
based on sTDP43 expression level. In  doing so, we observed a direct relationship between the 
extent of endogenous TDP43 mislocalization and sTDP43 expression (Supplemental Figure 4). 
These results indicate that TDP43 pathology may become more prevalent as sTDP43 expression 
is upregulated by neuronal hyperexcitability or other mechanisms.  
We failed to observe significant increases in cytoplasmic TDP43 deposition in transfected 
primary neurons (Figure 6H), potentially due to steric inhibition of sTDP43 localization and 
function by fusion with EGFP or HaloTag (Supplemental Figure 5). Placing the EGFP tag on the 
C-terminus of sTDP43 partially prevented cytoplasmic localization of sTDP43-EGFP 
(Supplemental Figure 5A-C) likely by masking the putative C-terminal NES. Similarly, we found 
that fusion of HaloTag with the N-terminus of sTDP43 significantly inhibits its binding to 
endogenous TDP43 (Supplemental Figure 5D,E). As such, N-terminal labeling of sTDP43 leaves 
the NES accessible but blocks association with endogenous TDP43, while C-terminal sTDP43 
labeling obstructs the NES but allows interaction with endogenous TDP43.  
 
sTDP43 lacks canonical functions of flTDP43 
To further examine the possibility that sTDP43 elicits loss-of-function toxicity, we assessed 
the ability of sTDP43 to participate in TDP43-related splicing activity. In keeping with TDP43’s 
function as a splicing repressor, TDP43 effectively blocks the inclusion of cystic fibrosis 
transmembrane conductance regulator (CFTR) exon 981,82 (Supplemental Figure 6A). In 
HEK293T cells expressing a CFTR minigene reporter, cotransfection with EGFP-flTDP43 resulted 
in proficient exon 9 exclusion as measured by PCR. In contrast, EGFP-sTDP43-1 expression 
failed to significantly affect exon 9 exclusion (Supplemental Figure 6B,C), suggesting that without 
the C-terminus, sTDP43 is incapable of TDP43-specific splicing60,64,65. 
Functional flTDP43 also participates in an autoregulatory feedback loop, in which flTDP43 
recognizes sequences within the TARDBP 3’UTR, triggering alternative splicing and/or 
polyadenylation and subsequent mRNA degradation83,84. To determine if sTDP43 is able to 
regulate endogenous TDP43 expression via this mechanism, we employed a TDP43 
autoregulation reporter consisting of an open reading frame (ORF) encoding the fluorescent 
protein mCherry upstream of the TARDBP 3’ UTR69 (Supplemental Figure 7A). In rodent primary 
cortical neurons expressing the TDP43 autoregulation reporter, cotransfection with EGFP-tagged 
flTDP43 resulted in a decrease in reporter signal, as expected. EGFP-labeled sTDP43-1 
displayed minimal effects on reporter fluorescence, suggesting that its ability to autoregulate 
TDP43 is impaired (Supplemental Figure 7B,C). Likewise, when expressed in HEK293T cells, 
sTDP43-1 exhibited a similarly muted effect on endogenous TDP43 at the transcript and protein 
level (Supplemental Figure 7D-F), consistent with poor autoregulation. Together, these results 
indicate that sTDP43 lacks many of the canonical functions of TDP43, including its splicing and 
autoregulatory abilities. 
  
sTDP43 colocalizes with markers of stress granules 
Previous studies suggested that sTDP43 associates with protein components of 
cytoplasmic stress granules, including G3BP1 and TIA165. Therefore, we immunostained for 
G3BP1 and TIA1 in HEK293T cells overexpressing EGFP-tagged sTDP43-1, before and after 
application of osmotic stress (0.4M sorbitol). Prior to sorbitol treatment, we noted substantial 
colocalization of sTDP43-1 with G3BP1 (Supplemental Figure 8A) and TIA1 (data not shown) in 
large cytoplasmic deposits; these structures were unique to cells transfected with sTDP43-1, 
suggesting that sTDP43 overexpression elicits the formation of irregular structures rich in stress 
granule components. However, when cells were stressed with 0.4M sorbitol we observed the 
formation of multiple small, punctate structures resembling stress granules that colocalize with 
both G3BP1 and TIA1, as well as endogenous TDP43 (Supplemental Figure 8B). Moreover, while 
osmostic stress drives flTDP43 to the cytoplasm, it has little effect on sTDP43-1 localization 
(Supplemental Figure 8C). These data confirm that sTDP43 localizes to stress granules, and 
further imply that sTDP43 production may be sufficient for the assembly of cytoplasmic stress 
granule-like structures even in the absence of stress. 
  
sTDP43 transcripts are enriched in murine and human lumbar motor neurons 
To determine if sTDP43 isoforms are produced in vivo and assess their expression in 
different regions of the central nervous system, we took advantage of a previous study that 
analyzed the transcriptome from murine frontal cortex and lumbar spinal motor neurons isolated 
by laser capture microdissection (Figure 7A)85. The most abundant splice isoform in frontal cortex 
homogenate was flTDP43, with predominant use of the conventional termination codon within 
TARDBP exon 6. However, splicing of the TARDBP locus, and in particular exon 6 and the 3’UTR, 
was dramatically altered in murine spinal motor neurons. In contrast to what was observed in 
frontal cortex, two splicing events corresponding to sTDP43 variants 1 and 2 were strongly 
favored in spinal motor neurons—these isoforms were upregulated ~12- and 10-fold, respectively, 
in lumbar spinal neurons relative to frontal cortex (Figure 7B,C). Further, while an ALS-associated 
TARDBP mutation (Q331K) did not affect sTDP43 transcript abundance, we noted age-related 
increases in sTDP43 mRNA levels in 20-month vs. 5-month old mouse cortices (Supplemental 
Figure 9). These data show that sTDP43 isoforms are not only detectable in vivo within the murine 
CNS, but they are also significantly upregulated by age and enriched in spinal motor neurons, a 
cell type selectively targeted in ALS. 
We also examined sTDP43 expression in human spinal neurons utilizing published RNA-
seq data from laser-captured lumbar spinal motor neurons, isolated from control and sporadic (s) 
ALS patient tissue86. Within this dataset, we identified specific transcripts corresponding to 
flTDP43, sTDP43-1, and sTDP43-2, and characterized the remaining TARDBP variants as 
“other.” Although there was no apparent difference in the abundance of any TARDBP transcripts 
between sALS and control motor neurons, we noted a dramatic enrichment of sTDP43-1 
transcripts in human spinal neurons, in comparison to flTDP43, sTDP43-2, and other TARDBP 
variants (Figure 7D,E). Furthermore, and in contrast to what we observed in rodent spinal 
neurons, sTDP43-1 was the predominant TARDBP splice isoform detected in human spinal 
neurons. To extend these findings, we also examined available RNA-seq data from spinal cord 
ventral horn homogenate from control and sALS patients87, as well as cerebellum and frontal 
cortex from controls, individuals with sALS, and patients bearing disease-associated mutations in 
C9ORF72 (C9ALS)88. Despite fundamental differences in sample preparation and sequencing 
methodology that prevented the direct comparison of transcript abundance between tissue types 
(Supplemental Figure 10A), we consistently observed significant expression of sTDP43-1 but not 
sTDP43-2 in several different regions of the CNS, including but not limited to spinal motor 
neurons, cerebellum, and frontal cortex, though there were no differences between control, sALS 
or C9ALS patient samples (Supplemental Figure 10B,C).  
 
Endogenously produced sTDP43 is detectable using specific antibodies 
To distinguish natively-produced sTDP43 species, we generated an antibody directed 
against the novel 18-amino acid C-terminus of sTDP43 (Figure 3D). This antibody specifically 
recognized EGFP fused to the sTDP43 C-terminus, suggesting that the sTDP43 tail is sufficient 
for immunoreactivity, and the signal was completely abolished by preincubation with the 
immunizing peptide (Supplemental Figure 11A). Furthermore, expression of artificial miRNAs 
(amiRNAs) targeting TDP4369,89 effectively reduced flTDP43 levels, as expected (Supplemental 
Figure 11B,C), and also decreased sTDP43 immunoreactivity (Supplemental Figure 11D,E), 
confirming antibody specificity. We further validated the sTDP43 antibody by transfecting 
HEK293T cells with EGFP-tagged sTDP43-1, isolating RIPA- and urea-soluble protein fractions, 
and immunoblotting for sTDP43. In previous studies, overexpressed sTDP43 was highly 
insoluble64; supporting this, we detected EGFP-sTDP43 exclusively in the urea-soluble fraction 
while EGFP-flTDP43 appeared in both RIPA- and urea-soluble fractions (Figure 8A). We also 
tested the sTDP43 antibody in human iNeurons treated with TEA or TTX to induce or abolish 
neuronal activity, respectively (Figure 8B). In these studies, TEA increased sTDP43 
immunoreactivity, while TTX reduced sTDP43 levels (Figure 8C), consistent with activity-
dependent upregulation of N-terminally labeled D2-TDP43 (Figure 2) and its detection by 
antibodies specific for the TDP43 N-terminus (Figure 1). Notably, sTDP43 antibodies detected 
numerous cytoplasmic puncta in TEA-treated neurons that were less apparent in vehicle- and 
TTX-treated cells, and the background nuclear signal was minimal in all cases. Identical sTDP43-
positive cytoplasmic puncta were observed in rodent primary mixed cortical neurons treated with 
bicuculline (Supplemental Figure 11F). These data indicate that sTDP43 antibodies selectively 
detect truncated, cytoplasmic, and insoluble TDP43 species by western blot and ICC, establishing 
them as useful tools for investigating sTDP43 deposition and its potential role in 
neurodegeneration. 
Based on the observed upregulation of sTDP43 splice isoforms in lumbar spinal neurons, 
we employed our newly-developed sTDP43 antibody for detecting sTDP43 in vivo within murine 
spinal cord sections. As predicted from the RNA-sequencing data, we detected cytoplasmic 
sTDP43 in anterior horn neurons from the lumbar spinal cord (Supplemental Figure 12A), 
confirming the subcellular distribution of the protein originally noted in vitro. We also observed 
strong colocalization of sTDP43 with GFAP-positive astrocytic projections within the spinal white 
matter, indicating astrocytic expression of sTDP43 (Supplemental Figure 12B). Subsequent 
studies confirmed that sTDP43 is endogenously produced by human iPSC-derived astrocytes 
(Supplemental Figure 13), suggesting that while sTDP43 is enriched within spinal neurons (Figure 
7), it is also synthesized by supporting glia.  
 
sTDP43 pathology is observed in ALS patient tissue 
Given that (a) sTDP43 is endogenously produced at relatively high levels in spinal motor 
neurons, (b) neuronal hyperexcitability is a conserved feature of ALS, and (c) sTDP43 is 
upregulated by neuronal activity and age, we suspected that sTDP43 may accumulate in 
individuals with sALS. To address this question, we immunostained human cortex and spinal cord 
sections from sALS, C9ALS, and unaffected control patients using antibodies that recognize the 
TDP43 N-terminus or our newly-developed sTDP43 antibodies (Figure 8D). As predicted, 
immunostaining with N-terminal TDP43 antibodies showed both a reduction in nuclear signal and 
the appearance of cytoplasmic inclusions selectively in ALS patient tissue. While control tissue 
exhibited low immunoreactivity for sTDP43 in both the cortex and spinal cord, we observed a 
striking accumulation of sTDP43 within cytoplasmic deposits in ALS spinal cord and cortex (Figure 
8E). sTDP43-positive inclusions closely colocalized with N-terminally reactive cytoplasmic 
aggregates but not residual nuclear TDP43, suggesting that sTDP43 antibodies specifically label 
cytoplasmic deposits in ALS tissue. In this limited case study, sTDP43 pathology appeared to be 
conserved between sALS and C9ALS (Supplemental Figure 14A), hinting at a conserved process. 
We also observed a tight correlation between conventional TDP43 pathology (nuclear exclusion 
and cytoplasmic aggregation) and sTDP43 deposition—in ALS samples, neurons displaying 
TDP43 nuclear exclusion almost always showed cytoplasmic sTDP43 pathology. Additionally, we 
noted several cells from ALS patients that exhibited sTDP43 deposits despite a normal nuclear 
TDP43 pattern, perhaps illustrating an early stage of pathology (Supplemental Figure 14B,C). 
Even so, we detected significant heterogeneity in sTDP43 pathology among ALS cases, indicating 
the presence of additional, unknown factors that could impact sTDP43 deposition or 
immunoreactivity. 
In light of endogenous sTDP43 detected within mouse spinal cord astrocytes 
(Supplemental Figure 12B) and human iPSC-derived astrocytes (Supplemental Figure 13), we 
asked if sTDP43 pathology might also be present within astrocytes. In sections from controls and 
sALS patients immunostained with sTDP43 antibodies, neurons and glia were identified by co-
staining with NeuN and GFAP antibodies, respectively (Figure 8F). Cytoplasmic sTDP43 
accumulations were detected in both NeuN-positive neurons and GFAP-positive astrocytes, 
suggesting that sTDP43 pathology is not limited to neurons. Taken together, these results 
demonstrate that endogenous sTDP43 accumulates within neurons and glia of individuals with 
ALS, supporting a potentially pathogenic contribution of sTDP43 isoforms to ALS pathogenesis. 
 
Discussion 
In this study, we show that neuronal hyperactivity leads to the selective upregulation of C-
terminally truncated TDP43 isoforms (sTDP43). These isoforms are intrinsically insoluble and 
accumulate within cytoplasmic aggregates by virtue of a NES present within a novel 18-amino 
acid C-terminus. sTDP43 also sequesters endogenous TDP43 within cytoplasmic aggregates and 
induces its clearance from the nucleus, thereby recapitulating signature pathologic changes found 
in the majority of individuals with ALS and implicating complementary gain- and loss-of-function 
mechanisms in disease pathogenesis. sTDP43 transcripts are enriched in spinal motor neurons, 
a cell type that is selectively vulnerable in ALS, and post-mortem samples from individuals with 
ALS show conspicuous accumulations of sTDP43 within affected neurons and glia. These 
observations suggest a fundamental link between neuronal hyperexcitability and TDP43 
pathology, two conserved features characteristic of both familial and sporadic ALS. Moreover, 
they raise the possibility that sTDP43 production and/or its accumulation are heretofore-
unrecognized contributors to neurodegeneration in ALS. 
A series of previous studies demonstrated that alternative TARDBP splicing gives rise to 
truncated TDP43 isoforms lacking the C-terminus that are highly insoluble when overexpressed 
in heterologous systems49,60,64. Here, we show for the first time that neuronal activity selectively 
upregulates these truncated isoforms, which we collectively labeled sTDP43, despite a 
simultaneous increase in mRNA encoding full-length TDP43. This discrepancy may arise from 
the relative inability of sTDP43 to effectively participate in autoregulation (Supplemental Figure 
7), or the presence of unique elements within the flTDP43 3’UTR leading to nuclear mRNA 
retention and/or destabilization61–63,83,84. As such, the activity-dependent and apparently selective 
upregulation of sTDP43, together with the widespread neuronal hyperactivity observed in ALS 
patients, animal models, and human iPSC-derived neurons26,28,34,35,42,43, may be a crucial factor 
driving sTDP43 deposition in ALS tissue. 
In keeping with previous studies65, overexpressed sTDP43 accumulates in the cytoplasm 
where it often forms large, insoluble inclusions. The low-complexity domain (LCD) within the 
TDP43 C-terminus promotes liquid-phase separation and aggregation90–94. Even so, our 
observations and those of others64,65 show that sTDP43 is relatively insoluble and prone to 
aggregation, despite lacking the LCD. A growing body of evidence suggests that proteins with 
complex, folded domains such as the TDP43 RNA recognition motifs (RRMs) are highly 
susceptible to aggregation95. Rather than promoting insolubility, the presence of LCDs within 
these proteins protects against misfolding and aggregation by enabling reversible phase 
transitions during conditions of supersaturation. Thus, LCDs may permit higher local 
concentrations of RRM-containing proteins than would otherwise be possible without misfolding 
and/or aggregation96. In this regard, the absence of the LCD may be directly responsible for the 
enhanced aggregation of sTDP43; indeed, several RNA-binding proteins display similar 
phenotypes upon removal of the LCD, including Pub1, Pab1 and Sup3596–99. 
Using predictive software, we identified a potential NES located within the novel 18-amino 
acid sTDP43 tail, and experimentally confirmed that this segment drives cytoplasmic sTDP43 
localization. This NES appears to be dominant over the functional NLS present within the N-
terminus of sTDP43, either due to a high affinity for nuclear exporters or because of enhanced 
accessibility of the NES at the extreme C-terminus of the protein. The previously annotated 
TDP43 NES68,100 exhibits leucine/isoleucine-rich sequences favored by exportin-1 (XPO1), an 
essential mediator of protein nuclear export101. Nevertheless, scant experimental evidence 
suggests that this sequence functions as a true NES. TDP43 and XPO1 do not interact with one 
another in vitro15,102, and unbiased proteomics studies have failed to identify TDP43 as an XPO1 
cargo protein103,104. Further, TDP43 localization is unaffected by XPO1 inhibition or deletion of the 
putative NES15. In contrast, the NES uncovered within the sTDP43 C-terminal tail is both 
necessary and sufficient for sTDP43 nuclear export, suggesting that it is a bona fide NES. 
sTDP43 lacks the C-terminal glycine rich domain required for splicing activity105; as such, 
sTDP43 is incapable of CFTR minigene splicing or effectively participating in TDP43 
autoregulation, which involves differential splicing of the TARDBP 3’UTR83,84. The C-terminal 
glycine rich domain is also required for toxicity upon TDP43 overexpression in yeast94. 
Nevertheless, sTDP43 overexpression was still lethal in neurons. We suspect that sTDP43-
related toxicity arises from a combination of factors, including (a) the NES within the new C-
terminal tail region provoking cytoplasmic sTDP43 deposition; (b) its interaction with endogenous 
flTDP43 via its N-terminus52,73,106; and (c) the presence of intact RRMs that enable sTDP43 to 
bind and potentially sequester cytoplasmic mRNAs. 
sTDP43 isoforms are highly conserved in humans, non-human primates, and lesser 
mammals at the transcript and protein levels. Such evolutionary conservation suggests that these 
isoforms fulfill unknown functions, perhaps involving a compensatory response to chronic 
neuronal hyperactivity or generalized stress. Intriguingly, sTDP43 transcripts are significantly 
enriched in murine motor neurons compared to frontal cortex homogenate, their expression 
increases with age, and sTDP43-1 is the dominant TARDBP species in human lumbar motor 
neurons, raising the possibility that spinal motor neurons accumulate potentially toxic levels of 
sTDP43 in response to aging and hyperexcitability. Future studies are needed to determine 
whether native sTDP43 performs an essential function in motor neurons or other cell types, and 
if sTDP43 contributes to the selective vulnerability of aged motor neurons in ALS107,108. 
By creating a unique antibody that recognizes the novel C-terminus of sTDP43, we 
detected cytoplasmic sTDP43 inclusions selectively within the spinal cord and cortex of ALS 
patients, including individuals with sALS and C9ALS. In addition, the presence of sTDP43 
deposits coincided with nuclear TDP43 exclusion, as predicted by sTDP43 nuclear export and its 
affinity for flTDP43. Although the aggregation-prone109 TDP43 C-terminus forms a core 
component of the cytoplasmic inclusions found in ALS patients110–117, emerging evidence 
suggests that N-terminal TDP43 fragments also contribute to ALS pathogenesis. N-terminal 
TDP43 fragments are observed in ALS patient spinal cord118,119, and in keeping with studies of 
RNA-binding proteins in yeast, the TDP43 RRMs misfold and aggregate in vitro without the C-
terminal LCD to maintain solubility65,95,97–99,120–122. Independent of the RRMs, the TDP43 N-
terminus enhances TDP43 aggregation and toxicity65,79,120,121, potentially adding to sTDP43 
insolubility and the impact of sTDP43 deposition in affected neurons.  
TDP43-positive cytoplasmic inclusions in ALS are not limited to neurons but are also found 
in astrocytes and oligodendrocytes123–126. Astrocytes help regulate extracellular glutamate levels, 
and their dysfunction in ALS may lead to impaired synaptic glutamate buffering in sporadic as 
well as familial ALS127–132. In addition to detecting endogenous sTDP43 production in cultured 
human astrocytes and murine spinal cord, we noted disease-specific astrocyte sTDP43 pathology 
in sALS patient tissue. Although the effect of sTDP43 accumulation in these cells remains to be 
determined, it is possible that sTDP43-induced astrocyte toxicity triggers a feed-forward 
mechanism in which reduced glutamate buffering results in neuronal hyperactivity, increased 
sTDP43 production, and subsequent neurodegeneration. 
Our work underlines the significance of previously identified TDP43 isoforms and 
highlights a pivotal connection between neuronal hyperexcitability and TDP43 pathology, two 
conserved findings in ALS. Many questions remain, including the function of sTDP43 isoforms, 
the extent and pervasiveness of sTDP43 pathology in ALS, and whether cell type- or species-
specific differences in sTDP43 expression contribute to the selective vulnerability of human motor 
neurons in ALS. Complementary investigations of sTDP43 splicing and its regulation are crucial 
if we are to determine if targeted manipulation of sTDP43 has the potential to prevent or slow 
motor neuron degeneration in ALS. 
 
Materials and Methods 
Generation and maintenance of iPSCs 
Fibroblasts were reprogrammed into iPSCs via transfection with episomal vectors encoding seven 
reprogramming factors133 and validated as previously described134. All iPSC lines were cultured 
in Essential 8 (E8) media (Gibco A1517001) on plates coated with vitronectin (Gibco A14700) 
diluted 1:100 in Mg2+/Ca2+-free phosphate buffered saline (PBS, Gibco 14190-144). Cells were 
passaged every 5–6d using 0.5 mM EDTA (Sigma E7889) dissolved in PBS followed by gentle 
trituration in E8 media with a P1000 pipette. All lines are verified mycoplasma-free on a monthly 
basis. 
  
Integration of Ngn1/Ngn2 cassette into iPSCs 
iPSCs were split and plated into a vitronectin-coated 6 well plate as described above, at a density 
such that cells were 50-70% confluent in clumps of 2-5 cells at the time of transfection. Following 
plating, cells were incubated overnight in E8 media with ROCK inhibitor (Fisher BDB562822), and 
changed into fresh E8 media the following morning. Thirty minutes prior to transfection (~24h after 
plating or when the density was 50-70%), cells were changed into mTESR-1 media (Cell 
Technologies 85850) and then transfected with 2.5 µg of donor DNA and 1.25 µg of each targeting 
construct (Supplemental Table 3) using Lipofectamine Stem (Invitrogen STEM00003) according 
to the manufacturer’s instructions. The following morning, cells were changed into fresh E8 media. 
Media was changed daily, and cells were screened for red fluorescence. When the partially 
positive colonies reached 100-500 cells, they were carefully scraped/aspirated using a P200 pipet 
tip and transferred to a new vitronectin-coated dish. This process was repeated, enriching the 
fluorescent cells until a 100% fluorescent colony was identified. This was then relocated to a new 
dish, and expanded for future use. The Ngn1/2 integration cassette and accompanying targeting 
constructs were a gift from M. Ward.  
  
iNeuron differentiation 
Day 0. Induced pluripotent stem cells were washed in PBS and incubated in prewarmed accutase 
(Sigma A6964) at 37°C for 8m. Four volumes of E8 media were added to the plate, and the cells 
were collected and pelleted at 200xg for 5m. The media was aspirated, and the pellet was 
resuspended in 1ml of fresh E8 media. Cells were counted using a hemocytometer, diluted, plated 
at a density of 20,000 cells/ml in E8 media with ROCK inhibitor and incubated at 37°C overnight. 
Day 1. Media was changed to N2 media (1x N2 Supplement (Gibco 17502-048), 1x NEAA 
Supplement (Gibco 11140-050), 10 ng/ml BDNF (Peprotech 450-02), 10 ng/ml NT3 (Peprotech 
450-03), 0.2 µg/ml laminin (Sigma L2020), 2 mg/ml doxycycline (Sigma D3447) in E8 media). Day 
2. Media was changed to transition media ((1x N2 Supplement, 1x NEAA Supplement, 10 ng/ml 
BDNF, 10 ng/ml NT3, 0.2 µg/ml laminin, 2 mg/ml doxycycline in half E8 media, half DMEM F12 
(Gibco 11320-033)). Day 3. Media was changed into B27 media (1x B27 Supplement (Gibco 
17504-044), 1x Glutamax Supplement (Gibco 35050-061), 10 ng/ml BDNF, 10 ng/ml NT3, 0.2 
µg/ml laminin, 2 mg/ml doxycycline, and 1x Culture One (Gibco A33202-01) in Neurobasal-A 
(Gibco 12349-015)). Day 6. An equal volume of B27 media without Culture One was added to 
each well. Day 9-21. All cultures underwent a half-media change every 3d in fresh B27 media.  
  
Immunocytochemistry 
Neurons were fixed with 4% paraformaldehyde (PFA; Sigma P6148), rinsed with PBS, and 
permeabilized with 0.1% Triton X-100 (Bio-rad 161-0407) in PBS. Neurons were then treated with 
10 mM glycine (Fisher BP381-1) in PBS, and incubated in a blocking solution (0.1% Triton X-100, 
2% fetal calf serum (Sigma F4135), and 3% bovine serum albumin (BSA, Fisher BP9703-100) in 
PBS) at room temperature for 1h before incubation overnight at 4°C in primary antibody diluted 
in blocking buffer (Supplemental Table 4). Cells were then washed 3x in PBS and incubated at 
room temperature with Alexa Fluor 488 goat anti-rabbit (Life Technologies A11034), Alexa Fluor 
goat anti-mouse 594 (Life Technologies A11032), or Alexa Fluor donkey anti-rabbit 647 (Life 
Technologies A31573) secondary antibody diluted 1:5000 in blocking solution for 1h. Following 
3x washes in PBS containing 1:10000 Hoechst 33258 dye (Invitrogen H3569), neurons were 
imaged via fluorescence microscopy. High resolution images were obtained on a Zeiss LSM 800 
with a 63x NA1.4 Oil/DIS Plan-Apochromat objective. Excitation was accomplished using 405, 
488, 561, and 633 nm lasers. 
  
Modulation of neuronal activity 
Half of the existing media was removed from mature human iNeurons and replaced with fresh 
media and drug such that the final concentration on the cells was 4 mM tetraethylammonium 
chloride (TEA, Sigma T2265), 2 µM tetrodotoxin citrate (TTX, R&D Systems 1078) or 25 mM 
glutamate (Sigma G1251) alongside a volume-matched vehicle control. Cells were incubated at 
37° C for 48h, then fixed, imaged, or harvested as needed. 
  
Monitoring calcium transients 
Mature iNeurons—differentiated as previously described from an iPSC line stably expressing 
gCaMP6f and mCherry48—were imaged for 100ms at 200ms intervals for a total of 100 frames, 
for a cumulative a 20s observation window. One location was imaged per well for 2-30 instances 
over a 6-12h period. Each neuron was identified as a region of interest using mCherry 
fluorescence, and the intensity of gCaMP6f signal was plotted over time. Individual traces were 
corrected for photobleaching, normalized to the median of each imaging period, and filtered for 
peaks below a discrete threshold to aid in spike identification. The number of peaks for each 
neuron and each imaging period was manually counted using a custom-designed graphical user 
interface. Events per second were averaged for each cell and compared across groups. 
  
CRISPR/Cas9 editing of iPSCs 
Oligos complementary to the target region (Supplemental Table 3) were annealed, digested, and 
ligated into the BbsI site in pX335-U6-Chimeric_BB-CBh-hSpCas9n(D10A) (Addgene #42335, 
deposited by Feng Zhang) or pX330S-4 (Addgene #58780, deposited by Feng Zhang) according 
to the protocol available from Addgene. iPSCs stably expressing Ngn1-2 under a dox-inducible 
promoter were split and transfected as described above with pX335 vectors encoding 
Cas9(D10A) and sgRNA pairs targeting sequences flanking the TARDBP start codon for D2-
TDP43 or stop codon for TDP43-D2. Cells were cotransfected with the appropriate HDR vector 
encoding the Dendra2 open reading frame flanked by 400 bp of sequence homologous to that 
surrounding the TARDBP start codon (D2-TDP43) or stop codon (TDP43-D2) (in pUC-minus(M), 
synthesized by Blue Heron, LLC). Fluorescent cells were selected and successively passaged as 
described above to generate iPSC colonies in which 100% of cells expressed Dendra2-labeled 
TDP43.  
  
Longitudinal fluorescence microscopy and automated image analysis 
Neurons were imaged as described previously69,70 using a Nikon Eclipse Ti inverted microscope 
with PerfectFocus3a 20X objective lens and either an Andor iXon3 897 EMCCD camera or Andor 
Zyla4.2 (+) sCMOS camera. A Lambda XL Xenon lamp (Sutter) with 5 mm liquid light guide 
(Sutter) was used to illuminate samples, and custom scripts written in Beanshell for use in 
μManager controlled all stage movements, shutters, and filters. Custom ImageJ/Fiji macros and 
Python scripts were used to identify neurons and draw both cellular and nuclear regions of interest 
(ROIs) based upon size, morphology, and fluorescence intensity. Fluorescence intensity of 
labeled proteins was used to determine protein localization or abundance. Custom Python scripts 
were used to track ROIs over time, and cell death marked a set of criteria that include rounding 
of the soma, loss of fluorescence and degeneration of neuritic processes71. 
  
RNA sequencing 
Raw reads from murine frontal cortex and spinal cord59,85,86, as well as human spinal cord, frontal 
cortex and cerebellum59,85,86, were downloaded from Gene Expression Omnibus (GEO) with the 
SRA Toolkit v2.9.2. Reads were trimmed with TrimGalore v0.6.0 using automatic adapter 
detection and a minimum Phred score of 20. For alignment-free transcript-level quantification, 
trimmed reads were quantified using Salmon v0.13.1 (Patro 2017) and imported into the RStudio 
using txImport v1.12.0 (Soneson 2015) to generate transcript-level summaries135,136. The 
Ensembl genome assemblies and transcript annotations from GRCh38.96 and GRcm38.96 were 
used as human and mouse references, respectively. For alignment-based analysis of mouse 
datasets, trimmed reads were aligned with hisat2 v2.0.5 and raw counts were quantified for 
unique splice donor/acceptor combinations present in unique TARDBP isoforms. In each case, 
splicing events were visualized using IG Viewer software (Broad Institute). 
 
qRT-PCR 
RNA was isolated using the RNeasy Mini Kit (Qiagen 74106), and cDNA was reverse transcribed 
from 1 ug of the resultant RNA with the Bio-Rad iScript kit (Bio-Rad 170-8891) in a reaction 
volume of 20 µl. 0.5 µl of cDNA was used for each reaction as a template for quantitative (q)PCR, 
which was performed using Power SYBR Green (Applied Biosystems A25742) using the primers 
listed in Supplemental Table 5. 
  
Plasmids 
Plasmids pGW1-EGFP(1)80, pGW1-TDP43-EGFP137, and pGW1-mApple137 were used both as 
experimental controls and to generate additional constructs (Supplemental Table 6). 
  
To generate pGW1-sTDP43-EGFP, a geneblock comprised of the sTPD43-1 open reading frame 
(ORF) flanked by ApaI and AgeI restriction enzyme sites was generated by Integrated DNA 
Technologies (IDT). This geneblock was digested with ApaI and AgeI and cloned into the 
corresponding sites immediately upstream of the EGFP ORF in pGW1-EGFP(1). 
  
To create pGW1-sTDP43(mNES)-EGFP, the sTDP43 open reading frame was amplified using a 
reverse primer to mutate the putative NES into five sequential glycine resides. The resulting 
amplicon was digested with ApaI and AgeI and cloned into corresponding sites in pGW1-
EGFP(1). 
  
To generate pGW1-EGFP(2), the EGFP open reading frame was PCR amplified from pGW1-
EGFP(1). The resultant amplicon was digested with HindIII and Kpn1 restriction enzymes and 
cloned into the corresponding sites in pGW1-CMV. 
  
To generate pGW1-EGFP-tail, sense and antisense oligomers with the sequence of the 18-amino 
acid tail were generated by IDT, designed such that annealing would result in cohesive ends 
identical to cut KpnI and NheI restriction enzyme sites. The annealed oligo was cloned into 
corresponding sites immediately downstream of the EGFP ORF in pGW1-EGFP(2). 
  
To generate pGW1-EGFP-tail(mNES), sense and antisense oligomers with the sequence of the 
18-amino acid tail in which the putative NES was replaced by 5 glycine residues were generated 
by IDT, designed such that annealing would result in cohesive ends identical to cut KpnI and NheI 
restriction enzyme sites. The annealed oligo was cloned into corresponding sites immediately 
downstream of the EGFP ORF in pGW1-EGFP(2). 
  
To create pGW1-EGFP-TDP43, the TDP43 ORF was PCR amplified from pGW1-TDP43-EGFP. 
The resultant amplicon was digested with KpnI and NheI restriction enzymes and cloned into the 
corresponding sites immediately downstream of the EGFP ORF in pGW1-EGFP(2). 
  
To generate pGW1-EGFP-sTDP43, the sTDP43-1 ORF was PCR amplified from pGW1-sTDP43-
EGFP. The resultant amplicon was digested with KpnI and NheI restriction enzymes and cloned 
into the corresponding sites immediately downstream of the EGFP ORF in pGW1-EGFP(2). 
  
To create pGW1-Halo, the HaloTag ORF was PCR amplified from pFN21A HaloTag PUM2 RBD 
R6SYE (a gift from A. Goldstrohm). The resultant amplicon was digested with XbaI and SbfI 
restriction enzymes and cloned into the corresponding sites in pGW1-CMV. 
  
To create pGW1-TDP43-Halo, the TDP43 ORF was PCR amplified from pGW1-TDP43-EGFP. 
The resultant amplicon was digested with NheI and AgeI and cloned into corresponding sites in 
pGW1 to make pGW1-TDP43. The HaloTag ORF was then amplified from pFN21A HaloTag 
PUM2 RBD R6SYE, digested with XbaI and SbfI restriction enzyme sites and cloned into the 
corresponding sites immediately downstream of the TDP43 ORF in pGW1-TDP43. 
  
To generate pGW1-sTDP43-Halo, the sTDP43-1 ORF was PCR amplified from pGW1-sTDP43-
EGFP. The resultant amplicon was digested with AgeI and NheI and cloned into corresponding 
sites immediately upstream of the HaloTag ORF in pGW1-Halo. 
  
To generate the TDP43 autoregulatory reporter137, a 3 kb segment extending from TARDBP exon 
6 to the 3’ UTR was amplified from genomic DNA. The resultant amplicon was digested with BsrGI 
and SfiI and cloned into corresponding sites immediately downstream of the mCherry ORF in 
pCAGGs-mCherry. 
  
Shuttle-RFP (pcDNA3.1-NLS-mCherry-NES) was purchased from Addgene (#72660, donated by 
B. Di Ventura and R. Eils). The CFTR minigene reporter was a gift from Y. Ayala, and pCaggs-
mCherry and pGW1-CMV were gifts from S. Finkbeiner. The shTARDBP and non-targeting 
shRNA constructs were purchased from Dharmacon (V3SH11240-224779127, VSC11712). 
  
All constructs were verified by Sanger sequencing, and described in Supplemental Table 6. 
  
Primary neuron cell culture and transfection 
Cortices from embryonic day (E)19-20 Long-Evans rat embryos were dissected and 
disassociated, and primary neurons were plated at a density of 6x105 cells/ml in 96-well plates, 
as described previously138. At in vitro day (DIV) 4, neurons were transfected with 100 ng pGW1-
mApple to mark cell bodies and 50-100 ng of an experimental construct using Lipofectamine 2000 
(Invitrogen 52887), as previously described14,71,137. Following transfection, cells were placed in 
either Neurobasal Complete Media (Neurobasal (Gibco 21103-049), 1x B27, 1x Glutamax, 100 
units/mL Pen Strep (Gibco 15140-122)) or NEUMO photostable medium with SOS (Cell Guidance 
Systems M07-500) and incubated at 37°C in 5% CO2. 
  
Culturing and transfecting HEK293Ts 
Human embryonic kidney (HEK) 293T cells were cultured in DMEM (GIBCO 11995065), 10% 
FBS (Gibco ILT10082147), 1x Glutamax, and 100 units/mL Pen Strep at 37°C in 5% CO2. 
HEK293T cells are originally female in origin, are easily transfected, and have been transformed 
with SV40 T-antigen. HEK293T cells were transfected with Lipofectamine 2000 according to the 
manufacturer’s instructions. 
  
Immunoprecipitation using HaloLink 
HEK293T cells were transfected with Halo-tagged constructs of interest. Two days after 
transfection, cells were collected in PBS and pelleted at 21,000xg for 5m. The cells were then 
resuspended in 100 µl lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1% Triton X-100, 0.1% sodium 
deoxycholate). After incubation on ice for 15m, cells were passed through a 27.5 G needle and 
pelleted at 21,000xg for 10m at 4° C. 100 µg of protein was then added to 100 µl of prewashed 
HaloLink resin (Promega G1914), which was prepared by washing and pelleting for 2m at 800xg 
3x in wash buffer (100 mM Tris pH 7.5, 150 mM NaCl, 1 mg/ml BSA, 0.005% IGPAL). Sufficient 
wash buffer was added to ensure an equal volume for all conditions (~400 µl), and samples were 
incubated on a tube rotator for 30m at room temperature. Samples were then pelleted at 800xg 
for 2m, saving the supernatant. The beads were then washed 3x in wash buffer, and resuspended 
in elution buffer (1% SDS, 50 mM Tris-HCl pH 7.5) and 10x sample buffer (10% SDS, 20% 
glycerol, 0.0025% bromophenol blue, 100 mM EDTA, 1 M DTT, 20 mM Tris, pH 8). Samples were 
then boiled at 95° C for 10m, and loaded onto a 10% SDS-PAGE gel alongside 10 µg of input 
protein and a fixed volume of supernatant to assess binding efficiency. The gel was run at 120 V, 
and samples were then transferred at 100 V at 4°C onto an activated 2 um polyvinylidene 
difluoride (PVDF) membrane (Bio-Rad 1620177), blocked with 3% BSA in 0.2% Tween-20 (Sigma 
P9614) in Tris-buffered saline (TBST) for 1h, and blotted overnight at 4°C with primary antibody 
in 3% BSA in TBST (Supplemental Table 4). The following day, blots were washed in 3x in TBST, 
incubated at room temperature for 1h with donkey anti-mouse 680 RD (Li-Cor 926-68072) and 
donkey anti-rabbit 800 CW (Li-Cor 925-32213) secondary antibodies, both diluted 1:5,000 in 3% 
BSA in TBST. Following treatment with secondary antibody, blots were washed 3x in TBST, 
placed in Tris-buffered saline, and imaged using an Odyssey CLx Imaging System (LI-COR). 
  
Differential solubility fractionation 
HEK293T cells were transfected in a 6-well plate with 3 µg of DNA/well using Lipofectamine 2000 
according to the manufacturer’s instructions. Two days after transfection, cells were collected in 
PBS and pelleted at 21,000xg for 5m. Cells were then resuspended in RIPA buffer (Thermo 
Scientific 89900) with protease inhibitors (Roche 11836170001) and incubated on ice for 15m. 
Lysates were then sonicated at 80% amplitude with 5s on/5s off for a total of 2m using a Fisher 
Brand Model 505 Sonic Dismembrenator (ThermoFisher). Samples were centrifuged at 21,000xg 
for 15m at 4°C, after which the supernatant was removed and saved as the RIPA-soluble fraction. 
The RIPA-insoluble pellet was washed in RIPA once more and resuspended in urea buffer (7 M 
urea, 2 M thiourea, 4% CHAPS, 30 mM Tris, pH 8.5) and incubated on ice for 5m. Samples were 
then centrifuged at 21,000xg for 15m at 4°C, and the supernatant was saved as the RIPA-
insoluble, urea-soluble fraction. The RIPA-soluble samples were quantified and 10-30 µg of 
protein/well was diluted in RIPA buffer with 10x sample buffer. For urea fractions, equal volumes 
of each sample across conditions was diluted in urea buffer and 10x sample buffer. The RIPA-
soluble samples were boiled for 10m before 10-30 µg of all samples were loaded onto a 10% 
SDS-PAGE gel with stacking gel and run at 120 V. The blot was then transferred and probed as 
described above. 
  
Immunohistochemistry in human tissue 
Paraffin-embedded human cortex and spinal cord obtained from the University of Michigan Brain 
Bank were cut into 5 μm thick sections and mounted on glass slides. Tissue samples were 
photobleached prior to immunofluorescence139. Briefly, slides were placed on ice, under a 7 Band 
Spectrum LED Light (HTG Supply 432W HTG-432-3W-7X) at 4°C for 12h. Slides were 
deparaffinized at 65°C for 20m, and rehydrated 5m sequentially in xylene (Fisher X3S-4), 100% 
ethanol (Fisher 3.8L), 95% ethanol, 70% ethanol, 50% ethanol, and PBS. Slides were then 
permeabilized with 0.1% Triton X-100 in PBS, and treated with 10 mM glycine in PBS. They were 
then incubated in a blocking solution (0.1% Triton X-100, 2% fetal calf serum, and 3% BSA in 
PBS) at room temperature for 1h before incubation overnight at 4°C in primary antibody diluted 
in blocking buffer (Supplemental Table 4). Slides were then washed 3x in PBS and incubated at 
room temperature with Alexa Fluor 488 goat anti-rabbit (Life Technologies A11034), Alexa Fluor 
goat anti-mouse 594 (Life Technologies A11032), and/or Alexa Fluor goat anti-chicken 647 (Life 
Technologies A21449) secondary antibody diluted 1:5000 in blocking solution for 1h. Following 
3x washes in PBS containing 1:10,000 Hoechst 33258 dye (Invitrogen H3569), slides were 
mounted in mounting media (Fisher SP15-500) and allowed to dry in the dark overnight before 
being imaged the following day. Images were acquired using a Nikon Microphot-FXA microscope 
(Nikon, 1985) in combination with a 60x oil-immersion objective, a QIClick CCD Camera (Q 
Imaging, 7400-82-A1), and an X-Cite Series 120 light source (Lumen Dynamics). 
 
Statistical analysis 
Statistical analyses were performed in R or Graphpad Prism 7. For primary neuron survival 
analysis, the open-source R survival package was used to determine hazard ratios describing the 
relative survival between conditions through Cox proportional hazards analysis71. Significance 
determined via the two-tailed t-test was used to assess differences between treatment groups for 
neuronal activity and transcript abundance via RT-PCR. The Kolmogorov-Smirnov test was used 
to assess differences between the distribution of TDP43 abundance in neurons under different 
activity conditions. One-way ANOVA with Tukey’s or Dunnett’s post-tests were used to assess 
significant differences among nuclear/cytoplasmic ratios, binding affinity, TDP43 splicing activity, 
and TDP43 autoregulation. Data are shown as mean ± SEM unless otherwise stated. 
  
Ethics statement 
All vertebrate animal work was approved by the Committee on the Use and Care of Animals 
(UCUCA) at the University of Michigan and in accordance with the United Kingdom Animals Act 
(1986). All experiments were performed in accordance with UCUCA guidelines. Rats (Rattus 
norvegicus) used for primary neuron collection were housed singly in chambers equipped with 
environmental enrichment. All studies were designed to minimize animal use. Rats were cared 
for by the Unit for Laboratory Animal Medicine at the University of Michigan; all individuals were 
trained and approved in the care and long-term maintenance of rodent colonies, in accordance 
with the NIH-supported Guide for the Care and Use of Laboratory Animals. All personnel handling 
the rats and administering euthanasia were properly trained in accordance with the UM Policy for 
Education and Training of Animal Care and Use Personnel. Euthanasia was fully consistent with 
the recommendations of the Guidelines on Euthanasia of the American Veterinary Medical 
Association. 
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Figure Legends 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Hyperexcitability drives TDP43 accumulation in human iNeurons.  
(A) Schematic of the cassette used to integrate Ngn1 and Ngn2 into the CLYBL safe harbor locus 
under a doxycycline-inducible (Tet-on) promoter. CLYBL, targeting sequence; Puro, puromycin 
resistance gene; pA, poly-A tail; P1,P2, promoters; RFP, mCherry; rTTA, reverse tetracycline-
controlled transactivator; Ngn1,2, Neurogenin1 and 2; T2A, self-cleaving peptide; TRE, 
tetracycline response element. (B) Timeline depicting the differentiation of iPSCs into forebrain-
like neurons within 2w of doxycycline addition. (C) The resultant neurons are RFP-positive and 
express the neuronal markers Vglut1 and Tuj1. (D) Spontaneous neuronal activity visualized by 
the Ca2+ reporter gCaMP6f at 2w. Activity was pharmacologically modulated with bath application 
of glutamate or TTX. Vehicle n=257, Glutamate n=327, TTX n=403, stratified among 3 replicates; 
****p<0.0001, one-way ANOVA with Dunnett’s post-test. (E) Treatment with TEA significantly 
increased neuronal activity. Vehicle n=312, TEA n=369, stratified among 3 replicates, 
****p<0.0001, two-tailed t-test. (F) Example traces depicting changes in gCaMP6f fluorescence 
for each condition. (G) Heat maps depicting global changes in activity. Each row represents one 
neuron, and each column represents a 20s observation window. Thirty intervals were collected 
over a 12h period. Box color indicates the relative firing rate of each cell at each timepoint ranging 
from low (blue) to high (red). (H) N-terminal TDP43 immunoreactivity was increased in TEA-
treated iNeurons and decreased in TTX-treated iNeurons, indicating a bidirectional relationship 
between activity and TDP43 abundance. (I) Density plot depicting the change in TDP43 
immunoreactivity between conditions. Vehicle n=110, TEA n=113, TTX n=96, 2 replicates, dashes 
indicate single neurons, *p<0.05, Kolmogorov-Smirnov test. (J) No such relationship was 
identified when TDP43 abundance is detected using an antibody directed against the C-terminus. 
(K) Density plot depicting the change in C-terminal TDP43 immunoreactivity between conditions. 
Vehicle n=187, TEA n=541, TTX n=443, 2 replicates, dashes indicate single neurons, not 
significant by the Kolmogorov-Smirnov test. Scale bars in (C), 50 µm top, 20 µm bottom. Scale 
bars in (H), (J), 20 µm. 
 
  
 
Figure 2. TDP43 species harboring the N- but not the C-terminus are regulated by neuronal 
activity.  
(A) Strategy for labeling native TDP43 in human iPSC-derived neurons using CRISPR/Cas9. 
Dendra2 (D2, green) was inserted 3’ to the TARDBP start codon (green arrow) or 5’ to the 
conventional stop codon (red arrow), enabling fluorescent labeling of the TDP43 N- or C-terminus, 
respectively. In iNeurons, N-terminally tagged TDP43 (B, D2-TDP43) appeared both nuclear and 
cytoplasmic in distribution, while C-terminally tagged TDP43 (C, TDP43-D2) was primarily 
nuclear. (D) Density plot depicting the fluorescence intensity of D2-TDP43 upon application of 
vehicle (n=158), TEA (n=250), or TTX (n=221). (E) Density plot depicting the fluorescence 
intensity of TDP43-D2 with addition of vehicle (n=96), TEA (n=145), or TTX (n=98). In (D) and 
(E), dashes indicate individual neurons from 2 replicates, **p<0.01, ****p<0.0001, Kolmogorov-
Smirnov test. Scale bars in (B) and (C), 20 µm. 
  
  
 
 
 
 
 
 
 
 
 
 
Figure 3. Hyperactivity drives alternative splicing of TARDBP. 
(A) Sashimi plot depicting splicing events for the TARDBP gene, assembled from HEK293T cell 
RNA-seq data59. Splicing events predicted to skip the majority of exon 6—encoding the TDP43 
C-terminus—are highlighted in black. (B) Schematic of transcripts predicted to result in full-length 
(fl) TDP43 and C-terminally shortened (s) TDP43. Green triangles indicate start codons, red 
triangles indicate stop codons, and PCR primers are color-coded. (C) qRT-PCR of human 
iNeurons treated with TEA or TTX, showing activity dependent upregulation of total and sTDP43 
or downregulation of sTDP43, respectively. ARC (activity related cytoskeleton associated protein) 
acts as a positive control for activity-dependent gene regulation. PCR products corresponding to 
each primer pair are shown below. Data were combined from 3 replicates, *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001, two-tailed t-test. (D) Schematic comparing flTDP43 and sTDP43 
proteins. Novel sTDP43 C-terminus is shown in purple; NLS, nuclear localization signal; RRM, 
RNA-recognition motif; GRD, glycine rich domain. 
  
  
 
Figure 4. sTDP43 accumulates within the cytoplasm due to a putative NES. 
(A) Rodent primary mixed cortical neurons were transfected with mApple and EGFP-tagged 
TDP43 isoforms, then imaged by fluorescence microscopy. (B) Amino acid sequence of the 
sTDP43 tail includes a putative NES identified through predictive software NetNES 1.1. Light blue, 
polar; purple, positively charged; green, hydrophobic residues. (C) sTDP43-EGFP was 
significantly more cytoplasmic in distribution compared to flTDP43-EGFP, while mutation of the 
putative NES (mNES) restores nuclear localization. EGFP n=481, flTDP43-EGFP n=385, 
sTDP43-EGFP n=456, sTDP43(mNES)-EGFP n=490, stratified among 3 replicates, 
****p<0.0001, one-way ANOVA with Dunnett’s post-test. (D) Rodent primary mixed cortical 
neurons were transfected with EGFP or EGFP fused to either the novel C-terminal tail of sTDP43 
or a tail harboring a mutated NES (mNES). (E) The C-terminal sTDP43 tail is sufficient to 
significantly mislocalize EGFP to the cytoplasm, and mislocalization depends on the NES. 
Shuttle-RFP, a construct with a strong NES, serves as a positive control for a cytoplasmic protein. 
EGFP n=2490, Shuttle-RFP n=2073, EGFP-tail n=1956, EGFP-tail(mNES) n=2482, stratified 
among 3 replicates, ****p<0.0001, one-way ANOVA with Dunnett’s post-test. Scale bars in (A) 
and (D), 20 µm.  
 
 
 
 
 
Figure 5. sTDP43 overexpression is neurotoxic.  
(A) Example of a single neuron expressing mApple and sTDP43-EGFP, tracked by longitudinal 
fluorescence microscopy. Fragmentation of the cell body and loss of fluorescence on Day 5 
indicates cell death. (B) The risk of death was significantly greater in neurons overexpressing 
sTDP43-EGFP and flTDP43-EGFP, in comparison to those expressing EGFP alone. EGFP n= 
869, flTDP43-EGFP n=708, sTDP43-EGFP n=732, stratified among 3 replicates, ***p<2x10-16, 
Cox proportional hazards analysis. Scale bar in (A), 20 µm. 
  
  
 
Figure 6. sTDP43 overexpression leads to the cytoplasmic deposition and nuclear 
clearance of endogenous TDP43.  
(A) Halo-tagged flTDP43 or sTDP43 were expressed in HEK293T cells and immunoprecipitated 
with HaloLink. Bound TDP43 was immunoblotted with a C-terminal TDP43 antibody. GAPDH 
served as a loading control. Input, (I); eluate, (E). (B) Quantification of data shown in (A), 
demonstrating the fraction of total TDP43 bound to flTDP43-Halo, sTDP43-Halo, or Halo alone. 
Data was combined from 3 replicates, *p<0.05, **p<0.01, one-way ANOVA with Dunnett’s post-
test. (C) HEK293T cells were transfected with EGFP or EGFP-tagged sTDP43, then 
immunostained using an antibody that recognizes the C-terminus of endogenous (Endo) TDP43. 
Red, nuclear regions of interest (ROIs) determined by DAPI staining. (D) Nuclear, endogenous 
TDP43 is reduced by sTDP43 overexpression in HEK293T cells. EGFP n=1537, sTDP43-EGFP 
n=1997, 3 replicates, ****p<0.0001, two-tailed t-test. (E) Cytoplasmic endogenous TDP43 is 
elevated by sTDP43 overexpression in HEK293T cells. EGFP n=129, sTDP43-EGFP n=113, 3 
replicates, ****p<0.0001, two-tailed t-test. (F) Primary mixed rodent cortical neurons were 
transfected with EGFP or EGFP-tagged sTDP43, then immunostained using a C-terminal TDP43 
antibody. Red, nuclear ROIs determined by DAPI staining. (G) sTDP43 overexpression resulted 
in a significant drop in nuclear, endogenous TDP43 in primary neurons (EGFP n=395, EGFP-
sTDP43 n=323, 3 replicates, ****p<0.0001, two-tailed t-test), but this was not accompanied by 
increases in cytoplasmic, endogenous TDP43 (H) (EGFP=394, EGFP-sTDP43=323, 3 replicates, 
ns by two-tailed t-test). Scale bar in (C), (F) 20 µm. 
 
Figure 7. sTDP43 transcripts are enriched in lumbar motor neurons.  
(A) Sashimi plots depicting TARDBP splicing in murine frontal cortex homogenate (red) or 
microdissected lumbar motor neurons (blue). (B) Both sTDP43-1 and sTDP43-2 splice events are 
highly enriched in lumbar motor neurons compared to frontal cortex homogenate. Graph depicts 
read counts normalized to reads per million for each library. Analysis includes 4 replicates, 
****p<0.0001 multiple t-test with the Holm-Sidak correction. (C) While sTDP43-1 and -2 each 
comprise ~1% of the total TARDBP transcripts in frontal cortex homogenate, they make up 17 
and 22% of total TARDBP transcripts in lumbar motor neurons, respectively. Frontal cortex n=6, 
lumbar motor neurons n=4, *p<0.05, **p<0.01, ***p<0.001, two-way ANOVA with Sidak’s multiple 
comparison test. (D) sTDP43-1 is enriched within lumbar motor neurons microdissected from both 
control (n=9) and sALS (n=13) patient tissue. (E) sTDP43-1 makes up the majority of total 
TARDBP transcripts in both control and sALS patient lumbar motor neurons.  
 
Figure 8. Endogenous sTDP43 is detectable in vivo by antibodies generated against its 
novel C-terminus.  
(A) Western blot of EGFP-tagged flTDP43 or sTDP43 overexpressed in HEK293T cells, 
demonstrating the insolubility of sTDP43 in RIPA buffer. Black arrowhead, endogenous TDP43; 
white arrowhead EGFP-flTDP43. (B) ICC using sTDP43 antibodies showed increased 
immunoreactivity in TEA-treated iNeurons and decreased immunoreactivity in TTX-treated 
iNeurons. (C) Density plot depicting the change in sTDP43 immunoreactivity between conditions. 
Vehicle n=300, TEA n=354, TTX n=333, 3 replicates, dashes indicate single neurons, *p<0.05, 
****p<0.0001, Kolmogorov-Smirnov test. (D) IHC comparing the distribution of N-terminal TDP43 
and sTDP43 in spinal cord and cortex from patients with sporadic ALS and controls. (E) 
Quantification of cells with cytoplasmic sTDP43 in control and ALS patient spinal cord (control 
n=115, ALS n=110, data representative of two control and three ALS patients, ****p<0.0001, 
Fisher’s exact test). (F) IHC demonstrating neuronal and glial sTDP43 accumulation in cortex 
from individuals with sALS and controls. Scale bars in (B), (D), and (F) 20 µm. 
